Liposomal Bupivacaine Cuts Movement Pain After CRS + HIPEC

This placebo-controlled trial shows incisional liposomal bupivacaine added to opioid PCIA markedly reduces early movement-evoked pain after cytoreductive surgery, but only modestly reduces opioid use and does not improve recovery quality.

liposomal bupivacainebupivacainelocal anestheticsincisional infiltrationpostoperative painCRS + HIPECcytoreductive surgeryopioid-sparingPCIArandomized controlled trialacute pain Pain / Palliative Care

Background Information

Can liposomal bupivacaine revolutionize post-surgical pain management in CRS + HIPEC?

Managing postoperative pain after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is challenging, and new solutions like liposomal bupivacaine could enhance recovery. Liposomal bupivacaine reduced movement-evoked pain from 70.8% to 19.6% within 72 hours compared to saline and decreased opioid use with no significant difference in quality of recovery. This study suggests potential benefits of liposomal bupivacaine over saline in managing incisional pain post-CRS + HIPEC, though not more effective than other existing analgesic methods. Liposomal bupivacaine offers effective pain reduction after CRS + HIPEC but is not superior to all standard techniques.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Zhang H, Gong Z, Li Y, Li B, Yu Y, Liu G, Ji Z, Zhang H, Yan S

Citation: Zhang H, Gong Z, Li Y, et al. Liposomal Bupivacaine Incisional Infiltration for Postoperative Analgesia After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Randomized Placebo-Controlled Trial. Pain and therapy. 2026;15(5):1569-1590. doi:10.1007/s40122-026-00876-1

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →